ProCE Banner Activity

ATLAS-A/B: Phase III Trial of Fitusiran, an Investigational siRNA Therapy Targeting Antithrombin, in Patients With Hemophilia A or B Without Inhibitors

Slideset Download
Conference Coverage
In the ATLAS-A/B trial, prophylactic treatment with fitusiran resulted in significant reductions in annualized bleeding rates compared with on-demand factor replacement therapy in patients with hemophilia A or B and no inhibitors.

Released: December 16, 2021

Expiration: December 15, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation